19:19 , Feb 21, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A peptidomimetic compound that inhibits the DCUND1-UBE2M interaction and neddylation of cullin 3 (CUL3) could be used to probe the role of the CUL3/DCN1 cullin-RING ligase complex in squamous cell lung carcinoma. Computational...
18:36 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other molecule...
19:03 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; musculoskeletal; neurology; renal

INDICATION: Multiple sclerosis (MS); tissue damage; ataxia; renal In vitro and cell culture studies identified a UBE2M-derived peptide inhibitor of the DCUND1-UBE2M interaction that could help treat NFE2L2-deficient diseases such MS, tissue damage, Friedreich’s ataxia and...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...